Radiation Oncology | @BostonCollege @uhmed @ColumbiaRadOnc @NYPhospital Alum | tweets= mine
Honolulu, HI
Joined March 2009
- Tweets376
- Following477
- Followers555
- Likes1.7K
Mark Mayeda retweeted
Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non–Small Cell Lung Cancer.
Read full article. brnw.ch/21wTwRe
Mark Mayeda retweeted
@weeloonong leads pub in @EurUrolOncol for #PATRIOT (#SBRT weekly vs every other day treatment for favourable risk #prostatecancer )
No stat diff in bioc fail (mFU of 91mo)
Planning to combine with @ZilliThomas #NOVALIS study (same design)
free link👉tinyurl.com/yyhd69c2
Mark Mayeda retweeted
SBRT superior to thermal ablation (and non invasive without tumor size limitations). This is without even accounting for use of advanced technology with adaptive RT or surface monitoring and gating, etc.
Fortunate to have many excellent urologists @LPonsky who have helped champion early studies.
@jeshoag @randy_vincejr @AdamCalaway
📢🚨 Hot off the press @TheLancetOncol for #kidneycancer! shorturl.at/kAGVd. SABR vs thermal ablation;
- Despite ⏫age, ⏬worse GFR, and ⏫tumours for SABR
- SABR ⬆️effective than TA (at 1, 2 and 5 yrs)
- esp for RCC >4cm
- same renal decline (p=0.75)
- similar F/U #radonc
Mark Mayeda retweeted
#PACE A published in European Urology! SBRT vs Radical prostatectomy. Spread the word #SBRT should be discussed with eligible patients @DrTolan @alison_tree @cpeedell @DrAndrewLoblaw @EmmaHall71 @ProfJOSullivan authors.elsevier.com/sd/arti… – at Kensington, London
Mark Mayeda retweeted
This is the beginning of the end for #prostatectomy in localised #prostatecancer. In future, prostatectomy should be reserved for patients with severe LUTS and large prostates. Patients deserve an honest discussion about PACE-A & Protect Trial results, & surgical learning curves
#PACE A published in European Urology! SBRT vs Radical prostatectomy. Spread the word #SBRT should be discussed with eligible patients @DrTolan @alison_tree @cpeedell @DrAndrewLoblaw @EmmaHall71 @ProfJOSullivan authors.elsevier.com/sd/arti…
Mark Mayeda retweeted
🚀groundbreaking news🎳❗️
➡️ every PCa patient should be aware of these results before choosing the treatment
👏@nickva1 @alison_tree @EmmaHall71 🇬🇧
#ProstateCancer #SBRT
Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised Prostate Cancer: Results of the PACE-A Randomised Trial out in @EUplatinum
sciencedirect.com/science/ar…
The PACE-A trial is a phase 3⃣ randomized study comparing patient-reported outcomes between stereotactic body radiotherapy☢️ (SBRT) and prostatectomy in men with low- to intermediate-risk localized #ProstateCancer
It assessed health-related quality of life, focusing on urinary incontinence, bowel function, and sexual health two years after treatment.
Results showed that SBRT led to significantly less urinary incontinence and better sexual function, while prostatectomy resulted in better bowel scores.
However, SBRT was associated with slightly more bowel issues. These findings provide important insights for treatment decisions in localized prostate cancer.
@nickva1
@royalmarsdenNHS
@alison_tree
@DrTolan
@EmmaHall71
Mark Mayeda retweeted
#PACE A published in European Urology! SBRT vs Radical prostatectomy. Spread the word #SBRT should be discussed with eligible patients @DrTolan @alison_tree @cpeedell @DrAndrewLoblaw @EmmaHall71 @ProfJOSullivan authors.elsevier.com/sd/arti…
Mark Mayeda retweeted
In PACE-B (@nickva1, #ASTRO23), only 3.5% of patients recurred after 5y. In our @Sunnybrook #SBRT series only 5% of fav int risk patients recurred after 10y (Kennedy T, #ESTRO24)
Maybe you could clarify what you meant by “common occurrence”?
What if your prostate cancer returns after radiation therapy (a common occurrence)? There is so much more than simple observation or hormone tx! Dr. Todd Morgan @wandering_gu presented new #AUA24 Guidelines supporting ablation, surgery, and repeat radiation. @FocalSociety
Mark Mayeda retweeted
🚨🚨RTOG 0848🚨🚨
Anatomically resectable PDAC randomized postoperatively
1st randomization:
Gemcitabine +/- erlotinib (no benefit with erlotinib)
🔥2nd Randomization🔥
+/- Chemoradiation, 50.4 Gy/28 fx + cape
✅⬆️ DFS w/ ☢️
✅N0, ⬆️DFS and OS (5y 48% vs 29%) w/ ☢️
#asco24
Mark Mayeda retweeted
DOSIS - RCT in pts with painful vertebral mets
Hypothesis: improved LC -> durable pain response
First randomized trial with 6 mo pain reduction as prim endpoint
N=63 pts randomized to SBRT vs conv. RT
Significant benefit of SBRT: 69.4% vs. 41.9% (p=0.02)
doi.org/10.1002/cncr.35310
Mark Mayeda retweeted
Pleased to share our secondary analysis of @NRGonc CC001 evaluating heterogeneity of treatment effect for patients receiving HA-WBRT. doi.org/10.1093/neuonc/noad2…
@OncoAlert #btsm #lcsm
Mark Mayeda retweeted
The standard of care for stage III NSCLC changes once again;
Say goodbye to Durvalumab for patients with mEGFR (ex19del & L858R). #radonc
astrazeneca.com/media-centre…
Mark Mayeda retweeted
In the #PSMA #PETimaging arm of the randomized PSMA-SRT trial @UCLA and @UCSF, M1 disease was detected in ~10% and there was 18% more treatment escalation than in the control arm. Will this lead to improved PSA outcomes? Analysis is planned for 2025.
sciencedirect.com/science/ar…
Mark Mayeda retweeted
Happy to share our experience of primary ablative radiotherapy for #breastcancer in people that are not surgical candidates. Safe and effective!
Lots of people to @ but special mention to @DMoorePalhares @hanbo_chen @benazir_mir
@Sunnybrook @UofTDRO
authors.elsevier.com/a/1iWBu…
Mark Mayeda retweeted
Bone Met week 2/5
Post-op RT after surgical stabilization, should you treat entire hardware?
YES
sciencedirect.com/science/ar…
Mark Mayeda retweeted
Radiation to asymptomatic bone metastases reduces SREs (incl fractures, cord compression).
Primary results of our phase 2 RCT ⚖️ were published (below).
If you don’t have access to the full manuscript 📑, please DM me. 🙏 #radonc #medonc
☢️🦴 In a multi-center RCT ⚖️ (n=78), radiation to high-risk asymptomatic bone metastases ⬇️ skeletal-related events and prolonged overall survival in metastatic solid tumors: brnw.ch/21wE43a #radonc @ErinGillespieMD
Mark Mayeda retweeted
#SBRT actually numerically better - will need more time to see whether it will be statistically superior.
Between PACE-A and B, SBRT is the new SOC option for intermediate risk prostate ca (better sexual and incontinence vs RP; same efficacy, more convenient than CRT)
@nickva1 late breaking abstract of PACE B; conventional #radiotherapy versus SABR for #prostatecancer. Non-inferiority primary endpoint for bPFS met. 1.44% difference in 5-yr bPFS b/w arms (~95%) each. No difference in GI tox, GU 2 tox ⬆️ with SABR up to 6-9mo later #radonc #pcsm
Mark Mayeda retweeted
RADICALS-RT trial was just updated at #ESMO23 by Dr. Noel Clarke. The trial compared adjuvant versus salvage RT in localized prostate cancer after radical prostatectomy. Similar benefit for MFS or OS.
